ABVC
ABVC BioPharma, Inc.
There isn't enough reported data to score ABVC yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ABVC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ABVC's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ABVC PE Valuation
ABVC has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ABVC Forward outlook
There aren't enough analyst estimates for ABVC to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ABVC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$1.38 | +$2.02 |
| Q2 2024 | -$2.18 | +$1.50 |
| Q1 2024 | -$2.77 | +$0.83 |
| Q4 2023 | -$2.97 | +$2.03 |
| Q3 2023 | -$3.40 | +$3.35 |
| Q2 2023 | -$3.68 | +$2.67 |
| Q1 2023 | -$3.60 | +$2.95 |
| Q4 2022 | -$5.00 | +$0.05 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 114% for ABVC versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ABVC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $796K | +104% |
| Q4 2024 | $2K | -9.2% |
| Q3 2024 | $389.3K | +2351% |
| Q2 2024 | $117.1K | +1818% |
| Q1 2024 | $1.2K | -99% |
| Q4 2023 | $2.2K | -100% |
| Q3 2023 | $15.9K | -62% |
| Q2 2023 | $6.1K | -98% |
UNH has the stronger quarterly revenue trend. Revenue is down 779% for ABVC versus down 0.4% for UNH.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -247% | -260 points |
| Q4 2024 | -16997% | +73609 points |
| Q3 2024 | 13% | +13579 points |
| Q2 2024 | -834% | +35078 points |
| Q1 2024 | -285841% | -284355 points |
| Q4 2023 | -90606% | -90074 points |
| Q3 2023 | -13566% | -4775 points |
| Q2 2023 | -35912% | -35257 points |
ABVC's operating margin was −247% last quarter, up 285595 points from the same quarter a year ago, near the top of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ABVC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$894.2K | -$354.4K |
| Q2 2025 | -$894.2K | +$119.9K |
| Q1 2025 | -$539.8K | -$66.7K |
| Q1 2024 | -$473.2K | +$1M |
| Q1 2023 | -$1.5M | +$1.6M |
| Q2 2022 | -$3.5M | -$2M |
| Q1 2022 | -$3.1M | -$1.7M |
| Q4 2021 | -$1.8M | +$1.4M |
ABVC has the stronger cash trend. Its trailing FCF is up 29% versus its history, compared with UNH at up 5.2%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ABVC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +598K shares |
| 1 year | +15% | +3.4M shares |
| 3 years | +706% | +23.3M shares |
| 5 years | +992% | +24.2M shares |
| Available history | +1423% | +24.9M shares |
ABVC has 27M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2021 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ABVC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ABVC Net Leverage
ABVC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ABVC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 51.7 | Neutral |
ABVC's weekly RSI is 43 (neutral) and its Stochastic is 52 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ABVC PE vs Healthcare Sector
ABVC has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ABVC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.00 | 4% below |
| 20 week MA | $1.07 | 10% below |
| 50 week MA | $1.36 | 29% below |
| 100 week MA | $1.60 | 40% below |
| 200 week MA | $2.06 | 53% below |
ABVC is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ABVC on trend strength, trading above more of its moving averages.
ABVC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.5 | $52.0 | +1% |
| 2021 | $52.0 | $37.7 | -27% |
| 2022 | $37.7 | $6.90 | -82% |
| 2023 | $6.90 | $1.16 | -83% |
| 2024 | $1.16 | $0.58 | -50% |
| 2025 | $0.58 | $2.43 | +319% |
| 2026 YTD | $2.43 | $0.96 | -60% |
ABVC's yearly returns have swung widely, from +319% in 2025 to −83% in 2023. It's down 60% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ABVC on returns for 2026, with the stronger performance.